This study is evaluating how safe a type of targeted therapy (Lenvatinib) is for the treatment of children, adolescents, and young adults with relapsed or refractory cancer.
This trial is treating patients with relapsed or refractory solid cancer, excluding osteosarcoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Malignancies
Participants will be enrolled into initial tumor-specific cohorts which will be expanded based on observed response. Participants will receive 14 mg/m^2 oral lenvatinib, once daily (QD) until progressive disease or unacceptable toxicity (up to approximately 1 year).
Recruiting Hospitals Read More